Pricing Log in Create free account
Friday 6 November 2026 Export IMVT’s income statement to Excel — free account

Immunovant, Inc.

IMVT Healthcare Biotechnology

EPS
−5.63%
Free cash flow
−5.96%

Quarter to June 2026, against a year earlier

30.53 2.14 +7.54%
Market cap
$5.9B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Immunovant, Inc. (IMVT) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Sep 2, 2026 5.07 Submission of matters to a vote of security holders
10-Q Jun 30, 2026 P1I2: 12 added · 20 removed · 35 modified
P2I1A: 40 added 		Share dilution
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Mar 31, 2026 1: 33 added · 20 removed · 100 modified
1A: 23 added · 21 removed · 127 modified
7: 21 added · 25 removed · 34 modified
8-K May 20, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Dec 31, 2025
8-K Feb 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 10, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 10, 2025 8.01 Other events
8-K Nov 21, 2025 5.02 Departure or appointment of directors or officers Officer departure
10-Q Sep 30, 2025
8-K Nov 10, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 3, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 27, 2025 5.07 Submission of matters to a vote of security holders
10-Q Jun 30, 2025
8-K Aug 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Mar 31, 2025
8-K May 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Dec 31, 2024
8-K Feb 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 7, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 29, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 12, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 9, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.